A new oral KRAS inhibitor is gaining momentum in colorectal cancer. The FDA has granted fast track designation to QTX3034 plus cetuximab (with or without FOLFOX) for KRAS G12D–mutated colorectal cancer (CRC). Phase 1 data showed a 25% confirmed response rate in CRC and pancreatic cancer patients, with a manageable safety profile and no dose-limiting toxicities.
The FDA has granted fast track designation to QTX3034—an oral, multi-KRAS inhibitor with preferential activity against the G12D mutation—in combination with cetuximab, with or without FOLFOX chemotherapy, for patients with KRAS G12D–mutated colorectal cancer (CRC). Quanta Therapeutics called it the first fast track designation based on clinical data for a KRAS G12D-targeted therapy in CRC.
The rationale for the combo is rooted in biology: blocking EGFR upstream with cetuximab helps trap KRAS in its inactive state more efficiently, amplifying the effect of QTX3034. Phase 1 data from 29 combination-arm patients showed an objective response rate of 33%, with a confirmed ORR of 25% across CRC and pancreatic ductal adenocarcinoma (PDAC) patients treated at the 1200 mg twice-daily dose.
Why it matters: KRAS G12D is one of the most common—and historically undruggable—oncogenic mutations in CRC. A well-tolerated oral inhibitor showing early clinical signals of efficacy could open a meaningful new treatment avenue for patients with limited options.
